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Exosomes are endosome-derived, 30–100nm small membrane vesicles released by most cell types including tumor cells. They
are enriched in a selective repertoire of proteins and nucleic acids from parental cells and are thought to be actively involved in
conferring intercellular signals. Tumor-derived exosomes have been viewed as a source of tumor antigens that can be used to
induce antitumor immune responses. However, tumor-derived exosomes also have been found to possess immunosuppressive
properties and are able to facilitate tumor growth, metastasis, and the development of drug resistance. These diﬀerent eﬀects of
tumor-derived exosomes contribute to the pathogenesis of cancer. This review will discuss the roles of tumor-derived exosomes in
cancer pathogenesis, therapy, and diagnostic.
1.Introduction
Membranous vesicle shedding from live cells was ﬁrst
observed in the early 1980s and was proposed to be a
mechanism through which cells discard inert debris [1–4].
Diﬀerent types of membrane vesicles are secreted by
cells, formed either at the surface of a blebbing plasma
membrane or inside internal cellular compartments [5].
Among them, a population of nanosized membrane vesicles,
termed “exosomes,” has gained interest for their pleiotropic
biological activity. Exosomes are deﬁned as vesicles formed
by “inward/reverse budding” of the limiting membrane of
the multivesicular bodies (MVBs) in the late endocytic
compartment and released upon the fusion of MVB with the
plasma membrane [6, 7]. They are characterized by a size of
30–100nm in diameter and a density of 1.13–1.19g/mL in a
sucrose gradient and can be sedimented at 100,000×g[ 5, 8].
Exosomes typically show a “cup-shaped” or “saucer-like”
morphology when analyzed by electron microscopy. Exo-
some secretion is observed from most cell types under both
physiological and pathological conditions, especially tumor
cells and hematopoietic cells including reticulocytes [2, 4, 9,
10],dendriticcells(DCs)[11],BandTlymphocytes[12–15],
platelets [16], mast cells [17, 18], and macrophages [19]. In
addition, exosomes are also released by epithelial cells [20],
ﬁbroblasts [21], astrocytes, and neurons [22]. The extent of
exosome secretion can be modulated in diﬀerent cell types
by either ligand cognition or stress conditions. For example,
radiation treatment is able to increase the level of exosome
secretion by tumor cells, a process possibly involving the
activation of p53 and the subsequent upregulation of the
transmembraneproteintumorsuppressor-activatedpathway
6 (TsAP6) [21, 23].
Exosomes contain cytosolic and membrane proteins de-
rived from the parental cells. The protein content large-
ly depends on their cellular origin and are generally en-
riched for certain molecules, including targeting/adhesion
molecules (e.g., tetraspanins, lactadherin and intergrins),
membrane traﬃcking molecules (e.g., annexins and Rab
proteins), cytoskeleton molecules (e.g., actin and tubulin),
proteins involved in MVB formation (e.g., Alix, Tsg101
and clathrin), chaperones (e.g., Hsp70 and Hsp90), sig-
nal transduction proteins (e.g., protein kinases, 14-3-3,
and heterotrimeric G proteins) and cytoplasmic enzymes
(e.g., GAPDH, peroxidases, and pyruvate kinases) [5, 8,
24]. Antigen presenting cell- (APC-) derived exosomes
are also enriched in antigen-presenting molecules includ-
ing MHC class I and class II complexes and costim-
ulatory molecules [25]. Tumor-derived exosomes usually
contain tumor antigens as well as certain immunosup-
pressive proteins such as FasL, TRAIL, or TGF-β [26].
In addition to proteins, functional RNA molecules including2 Clinical and Developmental Immunology
mRNA and microRNAs have also been identiﬁed in exo-
somes [27–29].
Exosomes are now recognized as important mediators of
cell-to-cellcommunication[30].However,howthesevesicles
interact with and regulate the function of target cells remains
largely unknown. Several types of interactions are proposed
based on indirect evidence and in vitro studies, including
(1) binding of vesicles to the surface of a recipient cell
through exosomal adhesion molecules, or phosphatidylser-
ine(PS)/lysophosphatidylcholineandcellularreceptors(e.g.,
LFA1, TIM1 and TIM4); (2) direct fusion of vesicles with
recipient plasma membrane after adhesion; or (3) inter-
nalization of vesicles into endocytic compartments through
receptor-mediated endocytosis or phagocytosis [5]. Also, the
symmetrical phatidylethanolamine repartitions in exosome
membranes may facilitate their absorption, but not fusion
w i t ht a r g e tc e l l ss u c ha sD C s[ 31].
The interaction between exosomes and target cells can
lead to direct stimulation of target cells via surface-expressed
growth factors or bioactive lipids, transfer of membrane
receptors, or delivery of proteins to target cells. Also,
the presence of mRNA and microRNA, termed “exosomal
shuttle RNA,” in exosomes suggests that genetic material
exchange could be an additional level of exosome-mediated
communication between cells [27].
There is still some confusion in describing diﬀerent
types of vesicles secreted by cells. The terms “exosomes,”
“microvesicles,” and “membrane particles” are sometimes
used interchangeably. Generally, the term “microvesicles”
refers to vesicles shed from the plasma membrane, have a
relatively larger size (100–1000nm) than exosomes and can
be sedimented at 10,000×g. The term “membrane particles”
refers to vesicles that also originate from plasma membrane,
but have a small size similar to exosomes [5]. In this review,
we will focus speciﬁcally on the various eﬀects of exosomes
on tumorigenesis.
2. Antitumorigenic Role of
Tumor-Derived Exosomes
2.1. Immunogenic Properties and Tumor Exosome-Based Can-
cer Vaccines. The protein composition of exosomes largely
reﬂects that of their parental cells and thus shows cell-type
speciﬁcity. In particular, tumor-derived exosomes contain
tumor-speciﬁcantigensexpressedintheparentaltumorcells.
Enrichment of tumor antigens such as melan-A [32], Silv
[33], carcinoembryonic antigen (CEA) [34], and mesothelin
[35] is observed in tumor-derived exosomes when compared
w i t hw h o l ec e l ll y s a t e s[ 26]. The observation that most
tumor cells release exosomes containing tumor antigens
suggests that tumor exosome-based cancer vaccines could
be developed. Indeed, tumor-derived exosomes have been
used as a source of tumor antigens to pulse DCs, resulting
in the transfer of tumor antigens to DCs that were able to
induce CD8+ T cell-dependent antitumor eﬀects in mice
[33]. In a similar human ex vivo model system, DCs pulsed
with exosomes derived from malignant eﬀusions expressing
tumor antigens cross-present the antigens to antigen-speciﬁc
cytotoxic T lymphocytes (CTLs) [32]. Recently, it was
reported that tumor exosome-loaded DCs eﬀectively elicited
tumor-speciﬁc CD8+ CTL response against autologous
tumor cells in patients with malignant gliomas [36].
Direct application of tumor-derived exosomes for the
enhancement of antitumor immunity also has been inves-
tigated. It was reported that tumor-derived exosomes could
induce speciﬁc antitumor responses when the parental
tumor cells were genetically modiﬁed to express pro-
inﬂammatory cytokines such as IL-18, IL-12, and IL-2 [37–
39] or when the parental tumor cells were subjected to
stress conditions. For example, heat-shocked lymphoma
cells release exosomes with increased levels of MHC and
co-stimulatory molecules and induce eﬃcient antitumor T
cell immunity [40]. Additionally, exosomes derived from
heat-shocked tumor cells were observed to contain elevated
levels of Hsp70 and elicit Th1-polarized immune responses
in vitro and in vivo in both autologous and allogeneic
murinemodels,suggestingthattheseexosomescanstimulate
antitumor immunity in an MHC-independent manner [41].
Moreover, it was reported that exosomes derived from
tumor cells engineered to express membrane-bound Hsp70
stimulateTh1andCTLantitumorimmunitymoreeﬃciently
thanthosederivedfromheat-shockedtumorcells[42].Heat-
stressedtumorcellswerealsofoundtoreleaseexosomes with
enrichedchemokinesthatcouldattractandactivateDCsand
T cells more potently and induce speciﬁc antitumor immune
response more eﬃciently than exosomes from untreated
tumor cells [43]. Furthermore, surface targeting of antigens
to exosome membranes can enhance the immunogenicity
of tumor-derived exosomes, as membrane targeting of the
superantigen staphylococcal enterotoxin A (SEA) [44]o r
chickeneggovalbumin(OVA)[45]resultedinenhancedCTL
activity and delayed tumor growth.
The promising results obtained in animal tumor models
led to several phase I clinical trials using tumor-derived exo-
somes or exosome-pulsed DCs as cancer vaccines [46, 47].
However, it is important to note that in animal experiments,
eﬀective antitumor immune responses were mostly achieved
when tumor-derived exosomes were loaded onto matured
APCs or were modiﬁed to contain high levels of pro-
inﬂammatory factors or stress proteins. The representative
studies on the immunogenicity of tumor-derived exosomes
and tumor exosome-based cancer vaccines are listed in
Table 1.
2.2. Induction of Tumor Cell Apoptosis. In addition to the
potential immunostimularoty eﬀects, a proapoptotic func-
tion of tumor-derived exosomes directly on tumor cells was
also reported. Exosome-like vesicles produced by human
pancreatic tumor cells were reported to increase Bax and
decreaseBcl-2expression,inducingtumorcellstowardmito-
chondria apoptotic pathway. These exosomes also induced
phosphatase and tensin homolog (PTEN) and glycogen
synthase kinase-3β (GSK-3β) activation and decreased
pyruvate dehydrogenase activity in treated cells, sequestered
β-catenin-dependent survival pathway, and counteracted the
constitutively activated phosphatidylinositol 3-kinase/Akt
survival pathway to drive tumor cells toward apoptosis [48].Clinical and Developmental Immunology 3
Table 1: Representative studies on the immunogenicity of tumor-derived exosomes and tumor exosome-based cancer vaccines.
Parental tumor type/exosome source Exosome
application/modiﬁcation Model Results References
Mouse mammary adenocarcinoma,
melanoma, mesothelioma,
mastocytoma, human melanoma
BMDC pulsed with exo
were injected into mice
with established tumor
Mouse
Exo transfer tumor antigen to DC, induce
CD8+ T cell-dependent antitumor eﬀects
on both syngeneic and allogeneic mouse
tumors
[33]
Malignant eﬀusions of melanoma
patients
MDDCs-pulsed exo
were used to stimulate
lymphocytes
Human
ex vivo
DCs pulsed with exo cross-present mart-1
antigen to and expand antigen-speciﬁc CTLs [32]
Human malignant glioma Human DCs were
incubated with exo
Human
ex vivo
DCs incubated with exo activate
glioma-speciﬁc CTL which kills autologous
glioma cells
in vitro
[36]
Human CEA+ colon, lung
carcinoma
E x ow e r ei s o l a t e df r o m
heat-stressed tumor cells
Mouse,
Human
ex vivo
Exo immunization eﬃciently prime
antigen-speciﬁc CTL with antitumor eﬀects
in mice; exo-pulsed autologous DCs from
CEA+ cancer patients induce
antigen-speciﬁc CTL response
[34]
Mouse B lymphoma Parental cells were
heat-shocked Mouse
Exo induce DC maturation and stimulate
both protective and therapeutic antitumor
immune responses
[40]
Mouse colon carcinoma and
melanoma
Parental cells were
heat-treated Mouse
Exo contain elevated levels of Hsp70, elicit
Th1 response and therapeutically regress
established autologous and allogeneic
tumors
[41]
Mouse melanoma
Parental cells were
engineered to express
membrane-bound Hsp
70
Mouse
Exo stimulate Th1 and CTL response more
eﬃciently than exo derived from
heat-shocked cells expressing cytoplasmic
Hsp70
[42]
Mouse lung carcinoma Parental cells were
heat-stressed Mouse
Exo contain enriched chemokines,
attract/activate DCs and T cells more
potently and induce antitumor response
[43]
Human CEA+ tumor cells
Parental cells were
transfected with
AdhIL-18
Human
ex vivo
Exo/IL-18 chemoattract DCs and T cells and
enhance Th1 cytokine release.
Exo/IL18-pulsed DCs induced potent CTL
response
[37]
Mouse OVA+ thymoma
Parental cells were
transfected with
AdmIL-12
Mouse
Vaccination of exo/IL-2 induces
antigen-speciﬁc Th1 and CTL responses and
inhibits tumor growth
[39]
Human renal cancer
Parental cells were
modiﬁed to express
GPI-IL-12
In vitro Exo/IL-12 promote IFN-γ release and the
induction of antigen-speciﬁc CTLs [38]
Mouse lymphoma
Exo were surfaced
anchored with the
superantigen SEA by
protein transfer
Mouse
Immunization with exo/SEA-TM eﬃciently
inhibits tumor growth and induces
tumor-speciﬁc CTLs
[44]
Mouse ﬁbrosarcoma
OVA antigen was
targeted to exo
membrane by
transfecting parental
cells with OVA coupled
to lactadherin C1C2
domain
Mouse
Tumors secreting exo-bound OVA elicit a
stronger anti-OVA response and grow slowly
in vivo
[45]
Human ovarian cancer ascites
Exo were puriﬁed from
malignant ascites and
quality assessed
Preceding of
a clinical trial
A method for the preparation of GMP-grade
exosomes used in combination of mature
DCs for a clinical trial is described
[46]
Ascites from colorectal cancer
patients
Exo were puriﬁed and
used to immunize
patients either alone or
with GM-CSF
Phase I
clinical trial
Exo therapy is well-tolerated; exo plus
GM-CSF induce beneﬁcial tumor-speciﬁc
CTL responses in patients with colorectal
cancer
[47]
Abbreviations: Exo, exosomes; MDDCs: monocyte-derived DCs; Ad: adenovirus; GM-CSF: granulocyte-macrophage colony-stimulating factor.4 Clinical and Developmental Immunology
The interaction of these exosomes with pancreatic cancer
cells also led to decreased expression of the intranuclear
target of the Notch-1 signaling pathway, thereby inhibiting
the Notch-1 survival pathway and activating the apoptotic
pathway [49].
Despite the potential antitumor eﬀects of tumor-derived
exosomes, it is still unclear whether the constant production
of exosomes by tumor cells is beneﬁcial or harmful for
their own survival in vivo. Notably, in cancer patients with
advanced disease, tumor-derived exosomes are produced
abundantly in the tumor microenvironment, however eﬀec-
tiveimmunostimulatoryorantitumoreﬀectsofthesevesicles
are rarely observed. In fact, there is substantial evidence
supporting a role of tumor-derived exosomes in preventing
antitumor immune responses and promoting tumorigenesis.
3. Protumorigenic Role of
Tumor-Derived Exosomes
3.1. Immunosuppressive Properties. The observation that
membrane vesicles shed from murine melanoma cell lines
inhibited the expression of the immune response region-
associated antigen by macrophages provided early evidence
that tumor-derived membrane vesicles is a possible mech-
anism whereby tumor-bearing hosts become immunocom-
promised [50]. More recently, diverse immunosuppressive
eﬀects of tumor-derived exosomes have been identiﬁed.
Tumor-derived exosomes were shown to directly suppress
the activity of eﬀector T cells. Certain tumor cell lines can
p r o d u c ee x o s o m e se x p r e s s i n gd e a t hl i g a n ds u c ha sF a s L
and TRAIL, both of which can trigger the apoptotic death
of activated T cells [51, 52]. Additionally, Epstein-Barr
Virus- (EBV-) infected nasopharyngeal carcinoma (NPC)
was shown to release exosomes containing high amounts
of galectin-9, which induces apoptosis of mature Th1
lymphocytes when interacting with the membrane recep-
tor Tim-3. These exosomes prevent galectin-9 from being
proteolytically cleaved and thus induce massive apoptosis
of EBV-speciﬁc CD4+ cells [53]. Moreover, ovarian tumor-
derived exosomes were found to down-modulate CD3-ζ
chain expression and impair TCR signaling [54], suggesting
that tumor-derived exosomes can also downregulate T cell
function in addition to direct killing. In addition, NKG2D-
dependent cytotoxicity of NK cells and CD8+ T cells was
inhibited by NKG2D ligand-containing exosomes derived
from human breast cancer and mesothelioma cell lines [55,
56]. Similarly, murine mammary carcinoma exosomes were
shown to promote tumor growth in vivo by suppressing
NK cell function [57]. Taken together, these observations
suggest that tumor-derived exosomes can negatively regulate
the eﬀector arm of the immune system, in particular T cells
and NK cells.
Tumor-derived exosomes can also target myeloid cells
to modulate their diﬀerentiation and function. Exosomes
derived from human melanoma cell lines and colorectal
carcinoma cell lines were shown to skew monocyte dif-
ferentiation into DCs toward the generation of myeloid-
derived suppressor cells (MDSCs) and exert TGF-β1 medi-
ated suppressive activity on T cells in vitro. Interestingly,
signiﬁcant expansion of MDSC-like CD14+HLA-DR-/low
and TGF-β-secreting cells was also found in the peripheral
blood of late-stage melanoma patients and high levels
of MDSCs is usually associated with poor responses to
tumor vaccines [58]. Similar eﬀects were observed in mouse
models where exosomes produced by murine mammary
carcinoma cells and melanoma cells targeted CD11b+
myeloid precursors in the bone marrow (BM) and inhib-
ited the diﬀerentiation of BMDCs by inducing IL-6 in
these precursor cells [59]. These myeloid cells were found
to switch their diﬀerentiation pathway toward an MDSC
phenotype and promote tumor growth, dependent on the
prostaglandin E2 and TGF-β molecules present on tumor-
derived exosomes [60]. MyD88 also appears to play a pivotal
role in melanoma exosome-mediated MDSC expansion and
tumor metastasis [61]. Similarly, the membrane-associated
Hsp72 on tumor-derived exosomes was reported to mediate
STAT3-dependent immunosuppressive function of MDSCs
bytriggering STAT3activationinaToll-like receptor-(TLR-)
2/MyD88-dependent manner [62], although the role of
TLR2 in this process remains controversial [63, 64].
The eﬀect of tumor-derived exosome on BM cells is
thoughttobeacoevolutionarystrategyoftheprimarytumor
and the tumor microenvironment [65]. Alteration of BM cell
behavior by tumor-derived exosomes can be mediated by
proteins or by transfer of genetic materials, such as mRNA
and microRNA, between tumor cells and BM cells, thereby
inﬂuencing the function of future populations of BM cells.
RNA transfer to BM cells by microvesicles released from
other tissue/cell sources and the transcription of tissue-
speciﬁc mRNA in BM cells has been observed [66, 67],
suggesting that a similar eﬀect also can be mediated by
tumor-derived exosomes.
In addition, tumor-derived exosomes can also support
thefunctionofregulatoryT(Treg)cells.Forexample,human
tumor-derived exosomes were found to selectively impair
the IL-2 response to cytotoxic eﬀector cells while supporting
Treg cell activities through a TGF-β-dependent mechanism
[35]. Tumor-derived exosomes were also reported to induce,
expand, and upregulate the suppressor functions of human
Treg cells as well as enhance their resistance to apoptosis
via a TGF-β- and IL-10-dependent mechanism [68]. A
similar eﬀect was observed with exosomes derived from the
malignant eﬀusion of cancer patients as these exosomes,
most of which have a tumor origin, helped maintain the
number and suppressive function of Treg cells [69].
Given that tumor-derived exosomes are capable of
altering APC function and enhancing regulatory cell activity
while at the same time are a source of tumor antigen, it
is tempting to speculate that tumor-derived exosomes may
also have the ability to promote tolerance to tumor-speciﬁc
antigens. Indeed, we have demonstrated that tumor-derived
exosomesbearingamodeltumorantigenwereabletoinduce
antigen-speciﬁc immunosuppression in a murine delayed-
type hypersensitivity model. We proposed a mechanism that
tumor-derived exosomes provide tumor antigens to DCs
as well as condition DCs toward a suppressive/tolerogenic
phenotype, resulting in the downregulation of antigen-
speciﬁc immune responses [70].Clinical and Developmental Immunology 5
3.2. Facilitation of Tumor Invasion and Metastasis. In addi-
tion to attenuating diﬀerent branches of the antitumor
immunity to help tumor cells survive immunosurvelliance,
tumor-derived exosomes have also been implicated in
facilitating tumor invasion and metastasis. By stimulating
angiogenesis, modulating stromal cells, and remodeling
extracellular matrix, tumor-derived exosomes have been
found to contribute to the establishment of a premetastatic
niche, generating a suitable microenvironment in distant
metastatic sites [65].
Early proteomic analysis of mesothelioma cell-derived
exosomes detected the presence of strong angiogenic factors
that can increase vascular development in the neighbor-
hood of tumor [71]. Melanoma-derived exosomes were
also found to stimulate endothelial signaling important for
tissue matrices remodeling and endothelial angiogenesis
[72]. Moreover, it was recently reported that melanoma
exosomes injected locally preferentially homed to sentinel
lymph nodes and prepared the lymph nodes to become
remote niches conducive to the migration and growth
of melanoma cells through the induction of molecular
signals for melanoma cell recruitment, extracellular matrix
deposition, and vascular proliferation [73]. Consistent with
these observations, it was reported that mice pretreated
with melanoma exosomes have a signiﬁcant acceleration of
melanoma metastasis in the lung [61].
Tetraspanins, which are constitutively enriched in exo-
somes, have been found to contribute to exosome-mediated
angiogenesis. It was reported that exosomes derived from a
pancreatic tumor line overexpressing D6.1A, a tetraspanin
associated with poor prognosis in patients with gastrioin-
testinal cancer, strongly induced endothelial cell branching
in vitro and angiogenesis in vivo in a rat model [74]. Tumor-
derived D6.1A stimulates the secretion of matrix met-
alloproteinase and urokinase-type plasminogen activator,
enhancestheexpressionofvascularendothelialgrowthfactor
expression in ﬁbroblasts, and upregulates the expression
of endothelial growth factor receptor as well as D6.1A
in sprouting endothelium. Moreover, the D6.1A-expressing
cell promoted angiogenesis independent of cell-cell con-
tact, highlighting the potential role of D6.1A-enriched
tumor-derived exosomes in inducing systemic angiogenesis.
Recently, exosomal Tspan8 (D6.1A) was found to contribute
to the selective recruitment of proteins and mRNA into
exosomes, including CD106 and CD49d, both of which were
implicated in the binding and internalization of exosomes
byendothelialcells.Inductionofseveralangiogenesis-related
genes, together with enhanced endothelial cell proliferation,
migration sprouting and maturation of endothelial cell
progenitors, were seen upon exosome internalization [75].
Tumor-derived exosomes were also found to incorporate
the Notch ligand Delta-like 4 (Dll4) and transfer the Dll4
protein into the cell membrane of host endothelial cells,
resulting in the inhibition of Notch signaling and the switch
of endothelial cell phenotype toward tip cells. This further
results in an increase in vessel density in vitro and an increase
in branching in vivo [76].
Another pronounced eﬀect of tumor-derived exosomes
is their ability to modulate the function of stromal cells
such as ﬁbroblasts. It was recently shown that exosomes
produced by a certain type of cancer cells contain TGF-
β on their surface in association with betaglycan and can
trigger SMAD-dependent signaling. Exosomal delivery of
TGF-β is capable of driving the diﬀerentiation of ﬁbroblasts
into myoﬁbroblasts, whose enrichment in solid tumor
represents an altered stroma that usually supports tumor
growth, vascularization, and metastasis. Exosomal TGF-β
delivery is also qualitatively diﬀerent from soluble TGF-β in
that they induce a more signiﬁcant elevation of ﬁbroblast
FGF2 production [77]. These observations suggest another
protumorigenic role of tumor-exosomal TGF-β in addition
to their immunosuppressive functions. However, it was also
noted that TGF-β is not universally present on exosomes
derived from all cancer cells.
Furthermore, exosomes shed by gynecologic neoplasias,
including ovarian cancer and breast cancer cells, were
found to contain metalloproteinases that have proteolytic
activity. These exosomes can increase extracellular matrix
degradation and augment tumor invasion into the stroma
[78–80]. It was suggested that CD44 is required for the
assembly of a soluble matrix which may serve as an exosome
carrier and/or a reservoir for growth factors, chemokines,
and proteases needed for tumor cell embedding and growth.
SelectiveknockdownofCD44resultedinastrikingreduction
of the metastasizing capacity of the highly metastatic tumor
in a rat pancreatic adenocarcinoma model [81].
Interestingly, tumor-derived microvesicles, which are
mostly shed from tumor plasma membrane, were found to
have certain eﬀects similar to exosomes, such as stimulating
angiogenesis [82, 83], modifying stromal cells [84], and
degradingextracellularmatrix[85–87],possiblybecausethat
they have comparable compositions and that the proteins
involved are present on both types of vesicles. However,
the vesicles reported to have a procoagulant eﬀect that
correlates with an increased risk of cancer-associated throm-
boembolism have been mostly microvesicles, rather than
exosomes,likelybecausethetissuefactorsandothercontents
with procoagulant activity such as PS and Mucin 1 mostly
reside in the cell surface membrane. Those microvesicles are
also thought to play an important role in supporting tumor
growth by inducing the local ﬁbrin deposits associated with
many solid tumors [88–92].
3.3. Transport of RNAs and Proteins for Tumor Survival
and Growth. The intercellular exchange of proteins and
genetic materials via exosomes is a potentially eﬀective
approach for cell-to-cell communication within the tumor
microenvironment [93]. In particular, transport of mRNAs
and microRNAs, from tumor cells to neighboring cells could
have signiﬁcant eﬀects on tumorigenesis. Glioblastoma-
derived exosomes were reported to transport mRNA into
recipient cells where it is functionally translated. These
exosomes stimulated glioma cell proliferation and promoted
tumor growth [28]. The let-7 microRNA family was found
to be selectively released in exosomes in a metastatic gastric
cancer cell line. Since the let-7 genes target oncogenes
including RAS and HMGA2 and generally play a tumor-
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could deliver oncogenic signals and promote metastasis
[94]. Moreover, exosomes can also be utilized by human
tumor virus for disseminating viral materials. For example,
exosomes released from NPC cells with latent EBV infection
contain EBV latent membrane protein 1 (LMP1) and viral
microRNAs. These exosomes were able to transfer LMP1
into recipient cells and activate growth-signaling pathway
[95]. Similarly, it was reported that the viral BART miRNAs
are released from EBV-infected NPC cells into exosomes.
These viral microRNAs could be detected in blood plasma
s a m p l e sf r o mN P Cx e n o g r a f t e dn u d em i c ea sw e l la sN P C
patients,suggestingthatexosomesenabletheseviralmiRNAs
to diﬀuse from the tumor site to the peripheral blood [96].
Tumor-derived exosomes may also transport apoptosis-
inhibitory proteins induced under stress conditions to
promote tumor survival. For example, survivin, a member
of the inhibitor of apoptosis protein family, can be absorbed
by cancer cells from extracellular media and inhibit their
apoptosis following genotoxic stress as well as increase their
replicative and metastatic ability [97]. It was found that
survivin was released into exosomes from cervical carcinoma
cellsatasigniﬁcantlyhigherlevelafterirradiation,suggesting
a potential exosome-mediated self-protective mechanism of
these cancer cells [98].
3.4. Drug Interference. The protumorigenic role of tumor-
derived exosomes is also reﬂected by their active participa-
tion in drug resistance through several mechanisms. One
mechanism is by drug exportation via the exosome pathway.
In human ovarian carcinoma cells that stably acquired
resistance to the cancer chemotherapy drug cisplatin, the
lysosomecompartment,wherethedrugusuallyaccumulates,
was reduced with more exosomes released compared to
cisplatin-sensitivecells.Moreover,whenthecellswereloaded
with cisplatin, exosomes released from cisplatin-resistant
cells contained 2.6-fold more platinum than those released
from cisplatin-sensitive cells, suggesting that exosome secre-
tion can be utilized by cancer cell to export anticancer drugs
[99]. A similar eﬀect was also observed in melanosomes, a
type of lysosome-related organelles in pigmented cells such
as melanoma cells [100]. One of the mechanisms by which
lysosomal vesicles sequester cytotoxic drugs is increased
acidiﬁcation and treatment with proton pump inhibitors
inhibited the acidiﬁcation process and increased the sensitiv-
ity of tumor cells to chemotherapy drugs [101]. In addition,
exosomes can also function to neutralize antibody-based
drugs. Exosomes secreted by HER2-overexpressing breast
carcinoma cell lines express a full-length HER2 molecule,
enabling them to bind to the HER2 antibody Trastuzumab
both in vitro and in vivo. The exosome-antibody interactions
inhibit the overall eﬀect of Trastuzumab on the proliferation
of cancer cells by reducing antibody binding to cancer cells
[102]. Such antibody sequestration was also demonstrated to
reduce the antibody-dependent cytotoxicity eﬀect on tumor
cells by immune eﬀector cells [103].
Taken together, tumor-derived exosomes exert pro-
tumorigenic eﬀects via pleiotropic mechanisms (Figure 1).
However, it is important to note that each of the numerous
eﬀects of exosomes reported was observed from exosomes
derived from only a few of a wide variety of cancerous
cell lines or types. Whether exosomes derived from a given
tumor will have the suﬃcient complexity to confer multiple
suppressive functions still needs to be determined [104]. It
is likely that the predominant regulatory role of exosomes
depends on their molecular phenotype and cell speciﬁcity. In
addition,environmentalfactorscouldalsoplayanimportant
role in determining the behavior and immunological impact
of tumor-derived exosomes.
4.ClinicalRelevanceof
Tumor-Derived Exosomes
As discussed above, tumor-derived exosome-pulsed DCs,
tumor-derivedexosomes,andexosomesisolatedfrommalig-
nant ascites all have been investigated for their ability to elicit
antitumor immune response in patients. However, although
these clinical approaches appear to be safe, there has been a
lack of clinical eﬃcacy of exosome-based vaccines in contrast
to the promising results obtained in many animal tumor
models.Becauseoftheirpotentialimmunosuppressiveprop-
erties, direct administration of tumor-derived exosomes may
actuallyresultinpromotedtumorgrowth.Therefore,clinical
studies have focused on the use of tumor-derived exosome-
loaded mature DCs [46] or ascites-derived exosomes [47],
which may include both APC- and tumor-derived exosomes,
together with proinﬂammatory factors. Still, the limited
number of clinical trials and patients recruited prevents a
conclusive evaluation of their eﬃcacy and prospect.
The protumorigenic potential of tumor-derived exo-
somes in cancer patients is supported by the observations
that in patients with breast or ovarian cancer, the level of
circulating exosomes and exosomes with tumor markers is
much higher than nonmalignant individuals and increases
with tumor progression [29, 105], and that exosomes
isolated from the sera of patients with oral or ovarian
cancer can impair T lymphocytes function and induce
their apoptosis [54, 106]. Therefore, it has been proposed
that removing immunosuppressive tumor-derived exosomes
fromthebloodcirculationofacancerpatientwouldimprove
antitumor immune response and delay the progression
and spread of malignancy. A novel hollow-ﬁber cartridge
(Hemopuriﬁer) system which is able to selectively deplete
circulating virus using a lectin-based resin with high aﬃnity
for glycosylated viral surface proteins was developed by the
San Diego biotechnology company Aethlon Medical [107].
Eﬀective removal of HIV particles has been demonstrated
[108–110] and this system has become an attractive device
for depletion of exosomes, which have a size similar to viral
particles and are also highly glycosylated on their membrane
proteins. The selective removal of exosomes can be enhanced
by attaching antibodies against exosome surface proteins
onto the resin of the cartridge. However, there are still
technical barriers in how to carefully distinguish tumor-
derived from nontumor-derived exosomes and concerns
such as the physiological outcome of removing all exosome-
like vesicles in the blood.
On the other hand, tumor-derived exosomes containing
tumor-speciﬁc protein and microRNA proﬁles have beenClinical and Developmental Immunology 7
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Figure 1: The protumorigenic role of tumor-derived exosomes. Tumor-derived exosomes help create an immunosuppressive tumor
microenvironment by inducing apoptosis and impairing the function of eﬀector T cells and NK cells, skewing DC diﬀerentiation into
MDSCsaswellaspromotingTregcellactivity.Theyalsocontributetotheestablishmentofapre-metastaticnichebyenhancingangiogenesis,
remodeling stromal cells, and promoting extracellular matrix degradation. Tumor-derived exosomes also function as delivery vehicles to
transfer microRNA and mRNA to neighboring cells. Moreover, tumor-derived exosomes can help tumor cells develop drug resistance by
exporting tumoricidal drugs or neutralizing antibody-based drugs.
proposed to be cancer diagnostic markers. Early detection
of cancer could be easily performed using exosomes isolated
from body ﬂuids such as blood plasma, serum, and urine.
Evidence supporting this approach include: (1) ovarian can-
cer-associated expression of claudin proteins can be de-
tected in the circulating vesicles of a majority of ovarian can-
cer patients [111], (2) in breast cancer patients increasing
levels of circulating vesicles expressing CEA and the cancer
antigen 15-3 is correlated with increasing size of tumors
[105], (3) exosomes expressing tumor markers can be iso-
lated from the sera of ovarian cancer patients and the
amount increases along with tumor progression [29]; and
(4)inglioblastomapatients,mRNAvariantsandmicroRNAs
characteristic of gliomas could be detected in serum vesicles
[28]. However, it was also found that not in all cases tumor-
derived exosomes were present in the blood circulation
[112]. In a study on tumor-derived exosomes in the serum of
glioblastoma patients, tumor-speciﬁc EGFRvIII was detected
in serum exosomes in 7 out of 25 patients [28]. We recently
demonstrated that tumor-derived exosomes with a chimeric
membrane surface tag could not be detected in plasma-
derived exosomes of mice bearing subcutaneous melanoma,
possibly due to the rapid uptake of tumor-derived exosomes
by APCs in the tumor microenvironment before they
have access to the blood circulation (unpublished data).
Therefore, diﬀerent types of tumor and possibly diﬀerent
tumor growth patterns may both aﬀect the accumulation
of tumor-derived exosomes in peripheral circulation. Thus
cautious interpretation is needed when using the presence of
tumor-derived exosomes in body ﬂuids as cancer diagnostic
markers.
5. Conclusion
Increasing evidence suggests that tumor-derived exosomes
can confer either antitumorigenic or protumorigenic eﬀects.
These seemingly controversial eﬀects can be the results of
complex interactions between exosomes, responding cells,
and environmental factors. In cancer patients, the immunos-
timulatory or immuosuppressive eﬀects of tumor-derived8 Clinical and Developmental Immunology
exosomesmayalsodependonthestageofcancerprogression
as well as the immune status. Notably, as close replicas
of their parental cells, tumor-derived exosomes are well
positioned to transmit the detrimental eﬀects of tumor cells
onto the immune system to facilitate their survival, growth,
and metastasis. Therefore, a better understanding of the
roles of tumor-derived exosomes in cancer pathogenesis is
needed to further improve anti-cancer therapeutics as well as
exosome-based cancer diagnostics.
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